Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
Want to see IN:EPIGRAL full AI Analyst Report?
Top Page
Epigral Ltd
(EPIGRAL)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹1,454.00
▲(16.85% Upside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by financially solid profitability and a significantly strengthened balance sheet, offset by weak and volatile cash generation (negative recent free cash flow). Technicals are supportive with strong upside momentum, while valuation is reasonable on P/E but less attractive on dividend yield.
Positive Factors
Strengthened balance sheet
Leverage has been cut materially to about 0.26x equity and equity has expanded, lowering financial risk. A stronger balance sheet improves resilience through industry cycles, sustains investment capacity for maintenance/capex, and preserves strategic optionality over the next 2–6 months.
Negative Factors
Weak cash generation
Free cash flow deterioration and low cash conversion reduce internal funding for growth or debt reduction, increasing reliance on external financing. Persistent weak FCF can constrain capital allocation, impair flexibility for cyclical downturns, and raise refinancing risk over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened balance sheet
Leverage has been cut materially to about 0.26x equity and equity has expanded, lowering financial risk. A stronger balance sheet improves resilience through industry cycles, sustains investment capacity for maintenance/capex, and preserves strategic optionality over the next 2–6 months.
Read all positive factors
Epigral Ltd (EPIGRAL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹53.59B
Dividend Yield0.46%
Average Volume (3M)1.86K
Price to Earnings (P/E)10.8
Beta (1Y)1.55
Revenue Growth-0.90%
EPS Growth-9.07%
CountryIN
Employees997
SectorHealthcare
Sector Strength45
IndustryChemicals
Share Statistics
EPS (TTM)93.51
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.38
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72.45
Revenue Forecast (FY)₹30.13B
Epigral Ltd Business Overview & Revenue Model
Company Description
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, ...
How the Company Makes Money
Epigral primarily makes money by manufacturing and selling bulk and value-added chemicals. Its key revenue stream is the sale of chlor-alkali products—most notably caustic soda (a high-volume industrial alkali)—to a broad base of industrial custom...
Epigral Ltd Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.67B | 25.27B | 25.50B | 18.94B | 21.69B | 15.50B |
| Gross Profit | 11.21B | 6.43B | 10.67B | 7.79B | 6.43B | 7.48B |
| EBITDA | 6.61B | 5.67B | 7.11B | 4.77B | 6.81B | 5.01B |
| Net Income | 4.02B | 3.32B | 3.58B | 1.96B | 3.53B | 2.53B |
Balance Sheet | ||||||
| Total Assets | 32.36B | 35.05B | 31.52B | 27.94B | 24.32B | 21.24B |
| Cash, Cash Equivalents and Short-Term Investments | 485.70M | 54.60M | 965.00M | 31.83M | 142.40M | 250.85M |
| Total Debt | 5.37B | 5.72B | 5.93B | 9.64B | 8.79B | 9.93B |
| Total Liabilities | 11.35B | 12.84B | 12.48B | 15.40B | 13.63B | 13.98B |
| Stockholders Equity | 21.01B | 22.21B | 19.05B | 12.54B | 10.69B | 7.26B |
Cash Flow | ||||||
| Free Cash Flow | 316.30M | -65.30M | 2.46B | -7.90M | 2.10B | -1.72B |
| Operating Cash Flow | 2.67B | 3.88B | 4.41B | 3.98B | 6.26B | 2.84B |
| Investing Cash Flow | -1.73B | -3.55B | -2.62B | -4.01B | -4.37B | -4.55B |
| Financing Cash Flow | -980.80M | -457.90M | -1.64B | -75.98M | -2.00B | 1.95B |
Epigral Ltd Technical Analysis
Positive
1244.30
Price Trends
1062.93
Positive
1080.11
Positive
1385.68
Negative
Market Momentum
43.80
Positive
55.51
Neutral
17.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Positive. The current price of 1244.3 is below the 20-day moving average (MA) of 1252.17, above the 50-day MA of 1062.93, and below the 200-day MA of 1385.68, indicating a neutral trend. The MACD of 43.80 indicates Positive momentum. The RSI at 55.51 is Neutral, neither overbought nor oversold. The STOCH value of 17.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:EPIGRAL.
Epigral Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹58.40B | 30.45 | ― | 0.13% | 9.68% | 6.17% | |
74 Outperform | ₹105.27B | 10.27 | ― | 0.41% | 4.88% | 66.43% | |
71 Outperform | ₹98.40B | 18.03 | ― | 0.44% | 13.29% | -2.17% | |
69 Neutral | ₹53.59B | 10.80 | ― | 0.46% | -0.90% | -9.07% | |
57 Neutral | ₹28.55B | 67.80 | ― | 0.03% | 9.88% | -40.57% | |
54 Neutral | ₹93.31B | 35.22 | ― | 0.16% | 14.80% | 63.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:EPIGRAL
Epigral Ltd
1,242.10
-640.30
-34.02%
IN:GUFICBIO
Gufic Biosciences Limited
284.70
-90.70
-24.16%
IN:MARKSANS
Marksans Pharma Limited
217.15
-31.47
-12.66%
IN:SHILPAMED
Shilpa Medicare Limited
477.10
126.13
35.94%
IN:STAR
Strides Pharma Science Ltd
1,142.05
450.23
65.08%
IN:SUPRIYA
Supriya Lifescience Limited
725.60
10.83
1.52%
Epigral Ltd Corporate Events
Epigral to Hold One-on-One Virtual Meet With Systematix Group on 8 May
May 6, 2026
Epigral Ltd has notified the exchanges that it will hold a one-on-one virtual meeting with institutional investor Systematix Group on 8 May 2026 via video conferencing, with the schedule subject to change based on exigencies of either party. The c...
Epigral Publishes FY26 Audited Results in Multiple Newspapers
May 4, 2026
Epigral Ltd has notified the stock exchanges that it has published its audited financial results for the fourth quarter and full year ended 31 March 2026 in multiple newspaper editions. The disclosure, made in line with SEBI’s listing and di...
Epigral posts Q4 FY26 earnings call audio for investor access
May 3, 2026
Epigral Limited has notified the National Stock Exchange of India and BSE Limited that an audio recording of its conference call discussing the financial results for the fourth quarter of fiscal year 2026 has been made available online. The disclo...
Epigral Publishes Postal Ballot Notice in Financial Express
Apr 19, 2026
Epigral Limited has notified the stock exchanges that it has published a postal ballot notice in the Financial Express, in both English and Gujarati editions, on 18 April 2026, in line with regulatory disclosure norms. The filing underscores the c...
Epigral launches electronic postal ballot to seek shareholder approvals
Apr 17, 2026
Epigral Limited has launched a postal ballot process to seek shareholder approval for certain special business resolutions through remote e-voting. In line with Ministry of Corporate Affairs circulars and SEBI listing rules, the company will condu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.